Stocks · News reference
Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Versigent (NYSE:VGNT) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
A hedge fund is betting on spinoffs and buyouts for several of its new portfolio holdings.
Argus Research analyst Bill Selesky maintains Versigent (NYSE:VGNT) with a Buy and raises the price target from $50 to $54.